Graph Convolutional Network for AD and MCI Diagnosis Utilizing Peripheral DNA Methylation: Réseau de neurones en graphes pour le diagnostic de la MA et du TCL à l'aide de la méthylation de l'ADN périphérique
Yuqin Qian,Xinlu Tang,Ruinan Shen,Yong Lu,Jianqing Ding,Xiaohua Qian,Chencheng Zhang
DOI: https://doi.org/10.1177/07067437241300947
2024-12-06
The Canadian Journal of Psychiatry
Abstract:The Canadian Journal of Psychiatry, Ahead of Print. ObjectiveBlood DNA methylation (DNAm) alterations have been widely reported in the onset and progression of mild cognitive impairment (MCI) and Alzheimer's disease (AD); however, DNAm is underutilized as a diagnostic biomarker for these diseases. We aimed to evaluate the diagnostic performance of DNAm for MCI and AD, both individually and in combination with well-established AD biosignatures.MethodsA total of 1,891 blood samples from Alzheimer's Disease Neuroimaging Initiative (ADNI) studies were used to identify potential candidate DNAm biomarkers. Multimodal clinical data from 635 samples (normal control (NC), n = 193; MCI, n = 352; AD, n = 90) in the TADPOLE dataset were utilized to construct eight different classification models using a graph convolutional network, a machine learning framework.ResultsAfter feature selection, 17 DNAm sites were selected for subsequent analysis. Remarkable differences in DNAm levels were observed at the screened DNAm loci in all three cohorts. Adopting DNAm features into multimodal models significantly improved the classification performance for three dichotomous subtasks (NC vs. non-NC, MCI vs. non-MCI, and AD vs. non-AD), especially when combined with cerebrospinal fluid (CSF) features for NC (area under the curve (AUC): 0.8534) and MCI classification (AUC: 0.7675). A weak correlation between DNAm and both magnetic resonance imaging and CSF features in the NC and MCI cohorts suggests good complementarity between modalities (correlation coefficient ≤0.2).ConclusionsOur study offers new insights into peripheral DNAm in MCI and AD and suggests promising diagnostic performance of models integrating epigenomics, imaging, or CSF biomarkers.Plain Language Summary TitleUsing Machine Learning and Blood-Based Genetic Markers to Help Diagnose Mild Cognitive Impairment and Alzheimer's DiseasePlain Language SummaryWhy Was the Study Done? Memory issues range from mild cognitive impairment, where people have more problems thinking or remembering than their peers, to Alzheimer's disease, which profoundly affects memory, thinking and independence. Accurate diagnosis is essential for disease intervention. Researchers have found that DNA methylation, which regulates gene expression, is altered in the blood of people with cognitive disorders. Despite its potential, DNA methylation hasn't been widely used for diagnosis. Our study investigated its effectiveness in diagnosing both mild cognitive impairment and Alzheimer's, either alone or alongside other indicators. How we did the study? We analyzed blood samples from 1,891 people in an Alzheimer's disease research dataset to find potential DNA methylation indicators. We then focused on 635 people with comprehensive clinical data, including healthy people, those with mild cognitive impairment, and Alzheimer's patients. We built machine learning models using many types of data, such as DNA methylation, brain imaging, or cerebrospinal fluid analysis and evaluated their diagnostic performance. These models excel at detecting subtle patterns in data that are not obvious to humans. What We Found? Our study identified 17 key DNA methylation markers that are valuable for diagnosis. We found that using DNA methylation data along with other clinical data, such as cerebrospinal fluid testing, significantly improved the ability to correctly classify who has cognitive disorder. Our results show that DNA methylation can provide additional information not available from other tests, highlighting its potential as a diagnostic tool. What This Means for You? Our study sheds new light on the potential of blood DNA methylation to diagnose mild cognitive impairment and Alzheimer's disease. Our models, which combine genetic information with brain imaging or cerebrospinal fluid testing, show promise in diagnosing cognitive disorders.
psychiatry